Market Signal Briefing

Toronto, Ontario--(Newsfile Corp. - October 8, 2025) - Tenet Fintech Group Inc. (CSE: PKK) (OTC Pink: PKKFF) ("Tenet" or the "Company"), an innovative analytics service provider, owner and operator of the Cubeler Business Development Platform, announced that it has filed an application on October 7, 2025, to revoke the failure to file cease trade order (the "FFCTO") issued on the Company's securities by the Ontario Securities Commission (the "OSC") on May 7, 2025. The Company's application is currently being processed, and no timetable was given for the completion of the process.

, /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release third quarter 2025 results after the market closes on Thursday, October 16, 2025. The earnings release and accompanying earnings presentation will be available on the company's website at www.cohenandsteers.com under "Company—Investor Relations—Earnings Archive."

The company will host a conference call on Friday, October 17, 2025 at 10:00 a.m. (ET) with access available via webcast and telephone. Chief executive officer, Joseph Harvey, chief financial officer, Raja Dakkuri, and president and chief investment officer, Jon Cheigh, will review the company's operating results and outlook and be available for questions.

Investors and analysts can access the live conference call by dialing 800-715-9871 (U.S.) or +1-646-307-1963 (international); passcode: 8494569. Participants should plan to register at least 10 minutes before the conference call begins. A replay of the call will be available for two weeks starting approximately two hours after the conference call concludes and can be accessed at 800-770-2030 (U.S.) or +1-609-800-9909 (international); passcode: 8494569. Internet access to the webcast, which includes audio (listen-only), will be available on the company's website at www.cohenandsteers.com under "Company—Investor Relations" under "Financials." The webcast will be archived on the website for one month.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

SOURCE Cohen & Steers, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

HomeIndustriesRetail/WholesaleCostco has said new perks for some members, like extra shopping hours and deals through Instacart, are paying offPublished: Oct. 8, 2025 at 4:46 p.m. ET

Costco Wholesale Corp. on Wednesday said it notched an 8% year-over-year sales gain through last month, continuing its streak of sales gains and easing Wall Street’s concerns about future growth.

Shares were up 2.5% after hours on Wednesday.

About the Author

Bill Peters is a Los Angeles-based MarketWatch reporter who covers earnings.

Partner CenterMost Popular

CrowdStrike Today

$509.95 +25.33 (+5.23%)

As of 04:00 PM Eastern

52-Week Range$292.50▼

$517.98Price Target$491.81

CrowdStrike Holdings Inc. NASDAQ: CRWD stock is up 43% in 2025. That’s about 3x the gains in the S&P 500, making the stock one of the best growth stories in the entire market. Much of this is due to the company's strong revenue growth from its AI-native Falcon platform.

Through its subscription-as-a-service (SaaS) model, CrowdStrike is helping companies take a targeted approach to their cybersecurity needs. This is evident in the company’s impressive year-over-year revenue growth, most of which is in the form of annual recurring revenue (ARR).

However, like many companies in the technology sector, CrowdStrike faces a key obstacle in its valuation. CRWD stock is delivering growth that merits a premium price, but it will take some time for the company to grow into its current valuation.

Falcon Flex Accelerates Adoption Across Cybersecurity Modules
The cybersecurity sector, along with—and largely because of—artificial intelligence (AI), is one of the two most important sectors for investors to own in the next decade. The company’s Falcon Flex platform allows customers to take an a la carte approach to their cybersecurity needs.

As of October 2025, the platform has approximately 30 modules, covering:

Cloud Security
Next-Gen Identity
LogScale Next-Gen SIEM

Most recently, CrowdStrike added Falcon for information technology (IT). These modules provide tools to handle security and IT operations, extending their utility beyond core cybersecurity and adding to the company’s total addressable market (TAM).

In CrowdStrike’s August 2025 earnings presentation, it cited impressive usage statistics regarding module adoption rates:

48% of its customers used 6 or more modules

33% of its customers used 7 or more modules

23% of its customers used 8 or more modules

What’s particularly relevant to these numbers is that the company continues to grow its ARR after offering several of its customers one or more modules for free after the company’s highly publicized outage in the summer of 2024. That means that customers aren’t just sticking with CrowdStrike, they’re adding to their commitments.

Leading Security’s Shift Into the Agentic AI Era
As part of CrowdStrike’s Fal.Con 2025 Investor Briefing, chief executive officer (CEO) George Kurtz declared CrowdStrike to be a leader in what he calls “the Agentic Era.” This is a new phase of cybersecurity designed for a world where artificial intelligence systems act autonomously.

As Kurtz describes it, traditional endpoint protection and even cloud-native defenses are no longer sufficient, because AI itself has become both a target and a potential threat vector. CrowdStrike’s approach is to secure the entire AI stack—from infrastructure and data to software and identities—through a unified platform that protects not just human users, but also machine and agentic identities.

Specifically, the company has launched its new Pangea module, which extends detection and response (DR) to AI environments. It offers “AI Detection and Response” and “AI Guardrails” that monitor model behavior for prompt injection, data leakage, and misuse. This next-generation approach allows security teams to detect anomalies in real time, even when threats arise from the AI models themselves rather than human attackers.

By unifying data, detection, and defense across human and non-human identities, CrowdStrike is positioning itself not only as a cybersecurity leader but as the protector of the AI ecosystem itself. This distinction could define the next decade of growth in the security industry.

Valuation Remains the Only Threat to the Bull Case
Justifiably or not, valuation is a sticking point for CRWD stock investors. The company’s rapid growth has brought with it significant investor interest. However, the stock has become expensive.

CrowdStrike Stock Forecast Today12-Month Stock Price Forecast:
$491.81
-2.52% Downside

Moderate Buy
Based on 48 Analyst Ratings

Current Price$504.53High Forecast$600.00Average Forecast$491.81Low Forecast$295.00CrowdStrike Stock Forecast Details

At the midpoint of the company’s most recent full-year guidance, it will bring in $3.66 in earnings per share (EPS). But for many investors, that’s not enough to justify a stock price of over $489 per share as of Oct. 7, particularly one with a trailing twelve-month price-to-earnings (P/E) ratio of around 137x, nearly double the sector average.

This is where it’s critical to understand what kind of investor you are as it relates to CrowdStrike. If the company achieves its target of $20 billion in ending ARR by fiscal year 2036, its stock will become significantly more appealing.

In fact, revenue growth of that magnitude, assuming analysts maintain the same revenue multiple, would put CrowdStrike’s market cap between $400 billion and $500 billion, putting it in the same category as the largest cloud/software companies.

But that growth won’t come in a straight line. After hitting its all-time high in July 2025, CRWD stock dropped almost 20% in two months. However, investors who bought that dip have been rewarded with a nice gain of over 14% in the last month, which is expected to last for several quarters. 

Should You Invest $1,000 in CrowdStrike Right Now?Before you consider CrowdStrike, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CrowdStrike wasn't on the list.

While CrowdStrike currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

October 08, 2025 16:47 ET

 | Source:

Willis Towers Watson US LLC

LONDON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, will announce its financial results for the third quarter on Thursday, October 30, 2025, before the market opens.

The company will host a conference call to discuss its financial results at 9:00 a.m. Eastern Time on Thursday, October 30, 2025. A live, listen-only webcast of the conference call will be available on WTW’s website. Analysts and institutional investors may participate in the conference call’s question-and-answer session by registering in advance here.

An online replay will be available at investors.wtwco.com shortly after the call concludes.

About WTW

At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance.

Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you.

Learn more at wtwco.com.

CONTACT

INVESTORS
Claudia De La Hoz | [email protected]

A float with people dressed as characters from the Walt Disney movie "Peter Pan" is seen as people attend the "Festival of Fantasy" parade at the Walt Disney World Magic Kingdom theme park in Orlando, Florida, U.S. July 30, 2022. REUTERS/Octavio Jones Purchase Licensing Rights, opens new tab

Oct 8 (Reuters) - Disney

(DIS.N), opens new tab said on Wednesday it will raise prices for certain tickets to its theme parks in the U.S. during key holidays such as the Thanksgiving week and New Year's Eve.

Prices for one-day tickets to Walt Disney World Resort in Orlando, Florida, will exceed the current $199 top price point, beginning with the holidays in 2026, the company said in a statement to Reuters.

Sign up here.

The starting and high-end price for tickets on sale through to October next year will remain unchanged.

Out of the seven ticket tiers at the Disneyland Resort in Anaheim, California, five will see price hikes of 3% or less, the lowest increase in several years. The lowest-priced ticket will remain unchanged at $104.

Currently, the cost of entry to Disneyland for the week of Thanksgiving — from November 24 to November 29 — as well as for the Christmas and New Year's week is $224, according to its website.

"Our commitment to creating magical experiences for everyone remains at the heart of what we do — and that will never change," Disney officials said in the statement.

Reporting by Juby Babu in Mexico City; Editing by Alan Barona

Our Standards: The Thomson Reuters Trust Principles., opens new tab

October 08, 2025 4:53 PM EDT | Source: Sitka Gold Corp.
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2025) - Sitka Gold Corp. (TSXV: SIG) ("Sitka" or the "Company") is pleased to announce it has entered into an agreement pursuant to which Beacon Securities Limited ("Beacon"), as lead underwriter, on behalf of a syndicate of underwriters (together with Beacon, the "Underwriters"), has agreed to purchase, on a "bought deal" private placement basis, 16,235,000 common shares that will qualify as "flow-through shares" within the meaning of the Income Tax Act (Canada) (the "FT Shares") of the Company at a price of $1.54 per FT Share (the "FT Issue Price") for gross proceeds to the Company of $25,001,900 (the "Offering").

"This bought deal financing, completed at a significant premium to market, highlights the growing recognition of our flagship RC Gold Project, which is rapidly evolving from an initial discovery into a major gold camp," said Cor Coe, Director and CEO of Sitka. "Combined with our current treasury, this financing provides funding and the ability to accelerate our efforts to further advance RC Gold as we focus on unlocking additional value from this exciting, district-scale gold discovery."

The Company will use an amount equal to gross proceeds from the sale of the FT Shares to incur eligible "Canadian exploration expenses" that will qualify as "flow-through mining expenditures" as such terms are defined in the Income Tax Act (Canada) (the "Qualifying Expenditures") related to the Company's RC Gold Project in the Yukon Territory, Canada on or before December 31, 2026. All Qualifying Expenditures will be renounced in favour of the subscribers effective December 31, 2025.

Subject to compliance with applicable regulatory requirements, the FT Shares will be offered to purchasers resident in all Provinces of Canada pursuant to (i) the accredited investor exemption under National Instrument 45-106 - Prospectus Exemptions ("NI 45-106") for aggregate gross proceeds of $5 million; and (ii) the listed issuer financing exemption under Part 5A of NI 45-106 and in reliance on the amendments to Part 5A of NI 45-106 set forth in Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (collectively, the "Listed Issuer Financing Exemption") for aggregate gross proceeds of $20 million. Any offering of FT Shares in Quebec pursuant to the Listed Issuer Financing Exemption will not commence until such time as the French Form 45-106F19 has been filed and posted on SEDAR+. The FT Shares sold pursuant to the Listed Issuer Financing Exemption will not be subject to resale restrictions under applicable Canadian securities laws. The FT Shares sold pursuant to the accredited investor exemption of NI 45-106 will be subject to the statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws.

The FT Shares may be donated by the initial purchasers to one or more charities and subsequently sold by the charities or may be sold by the initial purchasers to investors in follow-on transactions on a private placement basis in offshore jurisdictions as permitted and in the United States pursuant to an exemption from the registration requirements of the United States Securities Act of 1933 (the "U.S. Securities Act"), as amended.

There is an offering document related to the Offering (the "LIFE Offering Document") that can be accessed under the Company's profile on SEDAR+ at www.sedarplus.ca and on the Company's website at www.sitkagoldcorp.com. Prospective investors of the FT Shares being issued pursuant to the Listed Issuer Financing Exemption should read this LIFE Offering Document before making an investment decision.

Certain shareholders of the Company that hold participation rights may elect to purchase common shares of the Company at the FT Issue Price on a non-brokered private placement basis (the "Non-Brokered Offering").

The Company has agreed to pay the Underwriters a cash commission of 6.0% of the gross proceeds raised under the Offering and issue to the Underwriters such number of compensation options (each a "Compensation Option"), equal to 6.0% of the number of FT Shares sold pursuant to the Offering. Each Compensation Option shall entitle the holder thereof to acquire one common share of the Company at the FT Issue Price for a period of 24 months from the closing date of the Offering. No commission will be payable to the Underwriters with respect to the concurrent Non-Brokered Offering. The Compensation Options will be subject to a four month hold period under applicable Canadian securities laws.

The Offering and Non-Brokered Offering, if applicable, are expected to close on or about October 30, 2025 and are subject to the Company receiving all necessary regulatory approvals, including the approval from the TSX Venture Exchange.

The securities to be offered pursuant to the Offering have not been, and will not be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

About Sitka Gold Corp.
Sitka Gold Corp. is a well-funded mineral exploration company headquartered in Canada with over $14 million in its treasury and no debt. The Company is managed by a team of experienced industry professionals and is focused on exploring for economically viable mineral deposits with its primary emphasis on gold, silver and copper mineral properties of merit. Sitka is currently advancing its 100% owned, 431 square kilometre flagship RC Gold Project located within the Tombstone Gold Belt in the Yukon Territory. The Company is also advancing the Alpha Gold Project in Nevada and currently has drill permits for its Burro Creek Gold and Silver Project in Arizona and the Coppermine River Project in Nunavut, all of which are 100% owned by Sitka.

*For more detailed information on the Company's properties, please visit our website at www.sitkagoldcorp.com.

ON BEHALF OF THE BOARD OF DIRECTORS OF SITKA GOLD CORP.,

"Donald Penner"

President and Director

For more information, contact:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary and Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements about the Offering (including the completion of the Offering on the terms and timeline as announced or at all, the tax treatment of the FT Shares, the timing to renounce all Qualifying Expenditures in favour of the subscribers and use of proceeds of the Offering), the Non-Brokered Offering, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions and the Company's anticipated work programs.

These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things, that the Offering will not close on the anticipated timeline or at all on the anticipated terms; that the Company will use the net proceeds of the Offering as anticipated; that the Company will receive all necessary approvals in respect of the Offering and Non-Brokered Offering, market uncertainty and the results of the Company's anticipated work programs.

Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this news release, including, among other things, that the Offering will close on the anticipated timeline or at all and on the anticipated terms; that the Company will use the net proceeds of the Offering as anticipated; and that the Company will receive all necessary approvals in respect of the Offering and the Non-Brokered Offering, if applicable.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269697

VolitionRx Limited - Special Call

Company Participants

Marielle Herzog

Conference Call Participants

Alexandra Byrne
Eric Ariazi

Presentation

Alexandra Byrne

Great. Good morning, everyone. I'm Alexandra Byrne. I'm a reporter at GenomeWeb, and I will be your moderator for today's webinar. The title of today's webinar is beyond the genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery and it is sponsored by Volition. Our speakers today are Eric Ariazi, Chief Development Officer of Helio Genomics; and Marielle Herzog, Research and Development Director at Volition.

You may type in a question at any time during the webinar, you can do this through the Q&A panel, which appears on the right side of the webinar presentation. If you look to the bottom tray of your window, there is a series of widgets to enhance your webinar experience. And with that, I'll turn it over to Marielle.

Marielle Herzog

Thank you very much. Hello, everyone. Good morning, good afternoon, good evening, wherever you might be. I'm delighted to be here with you today for this women focusing on Nu.Q Discover and how Nu.Q technology could help to accelerate epidrug development.

About volition. So Volition is a multinational company. We have colleagues all around the world with 2 lab, 1 R&D lab and service in Belgium and 1 laboratory in the U.S. in San Diego. Our mission is really to stabilize and improve outcome of millions of people worldwide. But before diving into the core of this presentation, let's take a moment to have a look on the background behind the Nu.Q technology.

So nucleosome, the fundamental structural unit of chromatin, they play a crucial role in compacting DNA into chromosome and allowing the genome to fit into the cell nucleus.

Nucleosome in case of cell death are high cell

Recommended For You

Bitcoin's (CRYPTO: BTC) breakout remains structurally strong and well-supported, though Glassnode data indicates the market is transitioning into a more mature phase.

What Happened: According to Glassnode, rising leverage and measured profit-taking could inject near-term fragility, even as the broader uptrend remains fundamentally strong.

Bitcoin's rally across spot and futures markets is being fuelled by over $2.2 billion in ETF inflows, one of the strongest surges since April, alongside rising spot volumes and renewed institutional demand.

However, leverage has climbed sharply, with open interest hitting record highs and funding rates surpassing 8%, indicating the potential for short-term volatility or shakeouts.

In the options market, sentiment has shifted decisively bullish: implied volatility is up, skew has normalized, and traders are increasingly favouring call-heavy positions.

Yet this optimism has driven up the cost of upside exposure, creating a more crowded and volatile setup as the market juggles enthusiasm with leverage risk.

Also Read: Bitcoin Could Reach $150,000 If Q4 Seasonality Delivers, Trader Says

Why It Matters: Bitcoin has climbed to a new all-time high near $126,000, breaking through strong resistance between $114,000–$117,000 and highlighting renewed market strength.

On-chain metrics reveal robust accumulation by small-to-mid-sized holders (10–1,000 BTC), while whale selling has eased, signaling healthier, more organic demand.

This buying activity provides structural support around $117,000–$120,000, where 190,000 BTC last changed hands, marking a potential rebound zone if prices pull back.

Profit-taking has increased slightly but remains measured, consistent with a sustainable bullish phase rather than a market top.

Read Next:

Bitcoin Holds Near $122,000 On Sentiment Shift, Ethereum, XRP, Dogecoin Slide
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The rollout includes new bitcoin payment tools and a merchant wallet aimed at making cryptocurrency use easier for small businesses.

Darius Baruo
Oct 08, 2025 19:44

Gala Games introduces its first cross-world event in Townstar, offering unique NFT rewards and GALA tokens. The event runs from October 14 to 17, 2025.

The spirits of the Gala universe are awakening as Gala Games announces an unprecedented cross-world event starting with Townstar. This event marks a significant milestone for the gaming platform, inviting players to engage in a multi-game adventure with enticing rewards, according to Gala News.

Event Details and Rewards
Players are challenged to demonstrate their prowess in lemonade production during the haunted Townstar challenge. The event is set to run from October 14 to 17, 2025, offering participants the opportunity to earn more than just GALA tokens. The top 225 players on the leaderboard will receive an exclusive NFT, the "VEXI Scaremel (Epic)." This limited-edition NFT offers unique advantages such as affinity with the Candy Cart (Small) and 30 event points in VEXI Villages.

Exclusive NFT: VEXI Scaremel (Epic)
The "VEXI Scaremel (Epic)" NFT is described as a sugary spirit born from caramel and chaos, adding a deliciously dark charm to the player's inventory. It is designed for explorers with a penchant for adventure and a sweet tooth, enhancing the gaming experience with its unique attributes.

Continuing the Adventure
The Halloween-themed journey does not end with Townstar. Following the initial event, players can continue their adventure in VEXI Villages from October 23 to 27, 2025. This continuation promises to expand the storyline and offer further opportunities for gamers to engage with the Gala universe.

Gala Games' innovative approach with this cross-world event highlights its commitment to enhancing player experience and engagement through unique, multi-dimensional gaming opportunities.

Image source: Shutterstock

gala games
nft
townstar

The U.S. is poised to step into the institutional cryptocurrency arena in a historic way. Senator Cynthia Lummis, a well-known advocate for digital assets, recently confirmed that the United States government is prepared to begin funding its Strategic Bitcoin Reserve (SBR) at any moment.

Coinbase has activated staking services for New York residents allowing yields on Ethereum and Solana holdings after state regulatory approval, while users in California, New Jersey, Maryland, and Wisconsin collectively miss over $130 million in rewards from ongoing restrictions.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bloomberg analyst Eric Balchunas has highlighted how the BlackRock Bitcoin ETF (IBIT) has performed in comparison to the world’s largest asset manager’s older funds. This comes as the fund approaches the $100 billion milestone, which will make it the fastest to reach this milestone. 

BlackRock Bitcoin ETF Becomes Most Profitable Fund
In an X post, Balchunas revealed that the BlackRock Bitcoin ETF, which is approaching $100 billion, is now the most profitable fund for the asset manager by a “good amount.” The Bloomberg analyst also highlighted that this is a massive feat for the Bitcoin fund, considering its age in comparison to the other funds.  

The BlackRock Bitcoin ETF, which was launched last year, is currently generating an annual revenue of $244.5 million for the world’s largest asset manager. This is well ahead of BlackRock’s Russell 1000 Growth ETF, which is 25 years old and generates an annual revenue of $219.3 million, placing it in second place. 

Notably, the BlackRock Bitcoin ETF is the only fund on the list that has a single-digit age. The other of BlackRock’s funds are 12 years and above. Eric Balchunas also noted that IBIT was approaching $100 billion in assets under management (AuM), which could make it the fastest to reach this milestone. 

Source: Chart from Eric Balchunas on X
The Bloomberg analyst revealed that the Vanguard S&P 500 ETF currently holds this record, although it achieved this feat in 2,011 days. Meanwhile, the BlackRock Bitcoin ETF, which is just 437 days old, currently has $99.44 billion in assets under management, putting it on track to surpass this record by a considerable margin.

This comes as the BlackRock BTC ETF continues to lead the pack, with massive daily net inflows. On October 6, these Bitcoin funds saw $1.19 billion in daily net inflows, with IBIT accounting $970 million of these flows. Meanwhile, they recorded a daily net inflow of $875.6 million yesterday, with IBIT accounting for $899.4 million of these flows. 

IBIT Also Among Top 20 ETFs By AuM
Eric Balchunas also revealed that the BlackRock Bitcoin ETF is now in the top 20 in ETF assets following the rapid increase in its AuM. Based on its current AuM, IBIT is 19th on the list of largest ETFs, just ahead of Vanguard’s VIG and the “legendary” Technology Select Sector SPDR Fund. 

The Bloomberg analyst remarked that if the last 12 months are repeated, it may not take too long for the BlackRock Bitcoin ETF to break into the top 10. He noted that the fund took in $40 billion over the last 12 months and saw an 85% increase. He added that he will put the timeline at December 2026 if he has to give one. 

At the time of writing, the BTC price is trading at around $121,500, down over 2% in the last 24 hours, according to data from CoinMarketCap.

BTC trading at $121,899 on the 1D chart | Source: BTCUSDT on Tradingview.com
Featured image from Getty Images, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts.
Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

Saint-Petersburg Exchange (SPB), a major stock market in Russia, is now hosting futures trading for contracts based on the value of Bitcoin and BRICS assets. The exchange began preparations to provide the service right after the Bank of Russia authorized the offering of crypto derivatives to qualified investors this past spring.

Martinez acknowledges that the $2.82 range has proven a strong support for XRP, with buyers consistently stepping in to prevent deeper declines.

Cryptocurrency markets are climbing as Bitcoin's uptrend resumes, fueled by corporate BTC purchases and increased demand for U.S. spot Bitcoin ETFs.

CryptocurrencyTickerPriceBitcoin(CRYPTO: BTC)$123,519.26Ethereum(CRYPTO: ETH)$4,519.30Solana(CRYPTO: SOL)$227.06XRP(CRYPTO: XRP)$2.90Dogecoin(CRYPTO: DOGE)$0.2583Shiba Inu(CRYPTO: SHIB)$0.00001236Notable Statistics:

Coinglass data shows 129,160 traders were liquidated in the past 24 hours for $399.13 million.       
In the past 24 hours, top gainers include Zcash (CRYPTO: ZEC), Mantle (CRYPTO: MNT) and SPX6900 (CRYPTO: SPX).
Notable Developments:

Ethereum Is Stuck Below $4,500 Until This Key Indicator Catches Up, Analyst Says
‘Asia’s MSTR’ Metaplanet Meets Chart Level That Could Make Or Break It
ETH And Bit Digital’s BTBT Just Aligned — $5,000 ETH And $5 BTBT Could Be Next
DOGE And SHIB Are Done — BONK’s Chart Points To A 400% Moonshot
North Korean Hackers Set A Record With $2 Billion Crypto Heist in 2025: Report
Bitcoin Rebounds Above $122,000—But For ETH, XRP That May Be Bad News
Trader Notes: Castillo Trading highlighted that Bitcoin is showing a healthy bounce, with dips becoming shallower and increasingly difficult to catch.

This suggests strong momentum and the potential for continued upward movement, even though $120,000 bids remain unfilled.

Trader Tim noted that Bitcoin's recent close was weak, raising caution.

A strong weekly close could alleviate concerns, and altcoins might still catch longs, but for now, warning signs remain.

No top is being called, yet the outlook is not entirely clear.

Satoshi Stacker observed that overly aggressive bearish positions at recent lows triggered short liquidations, which are now fueling Bitcoin's rally.

Daan Crypto Trades commented that Bitcoin is demonstrating strong early October momentum.

Although the month still has a long way to go, Q4 is starting off well.

A gradual pace would help sustain the trend rather than risk an unsustainable spike.

IncomeSharks pointed out that Bitcoin continues to follow the expected pattern, while yesterday's small red candle led to unnecessary bearish posts that didn't reflect the market's true direction.

Read Next:

Bitcoin To $200,000 In 2025 Is Still In Play, Bitwise’s Matt Hougan Says
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Ethena Labs, the team behind the synthetic dollar USDe, has partnered with Jupiter Exchange, a decentralized exchange (DEX) aggregator on Solana, to introduce JupUSD, a new native stablecoin designed for the Jupiter ecosystem.

Controversial Bitcoin developer Luke Dashjr claims that he is tired of personally saving Bitcoin "every few years."   

"Even if we survive this attack by Core30, this situation, where I personally have to save Bitcoin every few years, needs to stop," Dashjr said in a recent social media post. 

According to Dashjr, Bitcoin will not be able to survive if it relies just on one man, so other developes need to step up. 

HOT Stories

Has Dashjr actually saved Bitcoin?  Despite his fringe and extreme ideological views, Dashjr is often credited with "saving" Bitcoin on numerous occasions.  

In 2013, he was part of the emergency group of developers who quickly fixed the inflation bug that caused a chain split between nodes and was close to eroding confidence in the original cryptocurrency.

You Might Also Like

Dashjr was also a loud opponent of the "SegWit2x" hard fork that was supposed to double the block size of the leading cryptocurrency. Despite being pushed by major mining companies and exchanges, the hard fork ultimately failed.

He also opposed Ordinals and inscriptions in order to prevent a UTXO blot. Dashjr claims that he tried to fix the issue before there was a huge spike in unspent outputs, but he was recovering from a hack back then. 

Most recent controversy As reported by U.Today, Dashjr was recently embroiled in yet another controversy, with leaked messages allegedly showing his plan to launch a hard fork in order to retroactively modify the blockchain with the help of a trusted multisig committee. 

The maintainer of the Bitcoin Knots client has clashed with Bitcoin Core developers over the decision to remove the default limit on OP_RETURN data. Dashjr, a staunch conservative, is an extremely loud opponent of lifting the limit.   

In response to backlash, Dashjr dismissed the published messages as "fabricated nonsense."

XRP (CRYPTO: XRP) is drawing fresh attention after Cardano (CRYPTO: ADA) founder Charles Hoskinson highlighted its untapped potential in decentralized finance, saying nearly $100 billion worth of idle XRP could soon enter yield-bearing ecosystems. 

The remarks came just as Nasdaq-listed Reliance Global Group Inc. (NASDAQ:RELI) announced it has added XRP to its corporate digital asset treasury.

Hoskinson Sees $100B XRP Unlocking DeFi LiquiditySpeaking during a livestream, Hoskinson said the XRP community has "almost a hundred billion dollars of XRP floating around that's yield-free," suggesting that regulatory clarity and real-world asset (RWA) integration could transform XRP into a major DeFi liquidity source.

"You try to match RWAs and all these emerging assets that now, because of changing regulation, can finally enter the space," Hoskinson said. 

"You pair them up with Bitcoin, ADA, XRP and that alone could get us $10–15 billion in TVL and a lot more transaction volume."

His comments underscore how DeFi protocols are beginning to explore interoperability with non-EVM blockchains.

Nasdaq-Listed Reliance Adds XRP To TreasuryReliance Global confirmed on Sep. 30 that it completed a purchase of XRP as part of its Digital Asset Treasury (DAT) strategy, joining its existing holdings of Bitcoin (CRYPTO: BTC), Ethereum (CRYPTO: ETH), and Cardano (CRYPTO: ADA). 

The company cited XRP's efficiency as the reason for inclusion, calling it a "measured step" toward diversified blockchain exposure.

CEO Ezra Beyman said the firm aims to build a balanced digital portfolio reflecting both innovation and long-term shareholder value. 

XRP Price Consolidates Ahead Of Breakout

XRP Breakout Analysis (Source: TradingView)

Technical analysis: XRP is trading near $2.91, consolidating inside a symmetrical triangle formation. 

Resistance remains capped at $2.93, where the 20-day EMA coincides with the upper boundary of the pattern. 

Immediate support rests at $2.85, followed by $2.74.

The Bollinger Bands are tightening, indicating reduced volatility that often precedes strong directional moves. 

A daily close above $2.93 could open the way toward $3.07, while failure to hold support may trigger a slide to $2.64.

Why It MattersXRP is rarely discussed as a DeFi engine, yet Hoskinson's $100 billion liquidity framing flips that narrative on its head.

If even a fraction of that idle supply migrates into yield markets, the impact on DeFi's total value locked could be seismic.

The timing alongside Reliance's Nasdaq-listed treasury move gives the narrative a rare blend of grassroots and institutional backing.

Such alignment hints at XRP's next frontier — not just payments or remittances, but deep integration with on-chain capital markets.

For traders, it raises the question of whether XRP is shifting from a transactional token into a structural pillar of DeFi itself.

Read Next:

Bitcoin Could 10x From Here, Says PayPal’s Ex-Boss—And This Pricing Model Agrees
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

PHILADELPHIA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Axalta Coating Systems Ltd. (NYSE: AXTA), a leading global coatings company, will release its third quarter 2025 financial results at 6 a.m. ET on Tuesday, October 28. The release and supporting materials will be posted to Axalta’s Investor Relations site.

In addition, the company will host a conference call at 8 a.m. ET on October 28. Chris Villavarayan, Chief Executive Officer and President, and Carl Anderson, Senior Vice President and Chief Financial Officer, will review the company's financial performance for the period. A live webcast of the conference call will be available here. A replay of the webcast will be posted shortly after the call and will remain accessible through October 28, 2026.

The dial-in phone number for the conference call is 1-800-245-3047 and the conference ID is AXALTA. For those unable to participate, a replay of the call will be available through November 4, 2025. The replay dial-in number is 1-844-512-2921. The replay passcode is 11160096.

About Axalta

Axalta is a global leader in the coatings industry, providing customers with innovative, colorful, beautiful and sustainable coatings solutions. From light vehicles, commercial vehicles and refinish applications to electric motors, building facades and other industrial applications, our coatings are designed to prevent corrosion, increase productivity and enhance durability. With more than 150 years of experience in the coatings industry, the global team at Axalta continues to find ways to serve our more than 100,000 customers in over 140 countries better every day with the finest coatings, application systems and technology. For more information visit axalta.com and follow us on LinkedIn.

October 08, 2025 2:30 PM EDT | Source: Railtown AI Technologies Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2025) - Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF) ("Railtown" or the "Company"), a leader in AI Agentic Frameworks and Observability tools, is thrilled to announce a Memorandum of Understanding (MOU) with Uniserve Communications Corporation (TSXV: USS) ("Uniserve"), a provider of managed IT, cloud, and data centre services with a 30-year operating history and over 10,000 businesses served. This strategic partnership positions Railtown to deliver its cutting-edge AI solutions to Uniserve's extensive network of approximately 3,000 small and medium-sized enterprise (SME) customers, significantly expanding Railtown's market reach and impact.

Partnership Overview

The collaboration integrates Railtown's advanced AI Agentic Frameworks and Observability tools with Uniserve's robust infrastructure, comprised of Data Centre solutions, ISP services, and Managed IT Services. This partnership enables Railtown to deploy scalable, cost-effective AI solutions tailored for SMEs, addressing the growing demand for modernization through the incorporation of AI agentic tools to maintain competitive relevance in a rapidly changing global marketplace.

Uniserve plans to increase its GPU compute capacity as its existing customer base begins the adoption of these types of agentic solutions in their day-to-day business operations.

By accessing Uniserve's established SME client base and national infrastructure, Railtown can rapidly scale and deploy its AI tools, empowering Canadian businesses to enhance their efficiency and competitiveness by providing them the foundational elements to build and deploy Agentic AI into their workflows and product offerings.

This partnership unlocks significant growth opportunities for Railtown by providing access to a market segment of Canadian businesses that are facilitated through Uniserve's management services. Railtown's AI tools will enable Uniserve's SME clients to implement modernization strategies, driving operational improvements and deepening Railtown's position as a key player in Canada's AI ecosystem.

Strategic Benefits for Railtown

Expanded Market Access: Railtown gains direct access to Uniserve's 3,000 SME customers, amplifying the reach of its AI Agentic Frameworks and Observability tools. Scalable Deployment: Uniserve's infrastructure supports the rapid deployment of Railtown's AI solutions tailored to SME needs. Revenue Growth Potential: This partnership is a further addition to Railtown's strategy of developing and growing its compute centric revenue pipeline. Strengthened Market Position: Collaborating with Uniserve reinforces Railtown's leadership in delivering practical AI solutions, enhancing its reputation as a trusted partner for Canadian businesses.Driving SME Innovation

By combining Railtown's AI expertise with Uniserve's established infrastructure and client relationships, the partnership is poised to deliver transformative AI solutions that address the unique needs of SMEs. These solutions will help businesses streamline operations, improve margins, and compete more effectively in a rapidly evolving market.

Cory Brandolini, CEO of Railtown, stated: "Partnering with Uniserve is a meaningful step forward in bringing accessibility to our AI Agentic Frameworks and Observability tools to the vast long tail SME audience. This collaboration not only accelerates the adoption of our technology but also positions Railtown's products to be a key technical layer at the forefront of driving AI compute resources and part of Canada's AI innovation ecosystem. Shared compute revenue streams will vastly out preform traditional SAAS models."

Kwin Grauer, Chairman and Interim CEO of Uniserve, added: "Railtown's AI solutions enable us to enhance our service offerings and deliver cutting-edge technology to our SME customers, meeting the growing demand for AI-driven modernization. This will also serve as a natural kickoff point to build our GPU compute capacity to serve the growing need among our customers for these types of solutions for their business needs."

About Railtown AI Technologies Inc.

Railtown develops AI Agentic Frameworks and Observability tools designed to empower businesses to build, deploy, and manage AI solutions efficiently, driving innovation and growth.

About Uniserve Communications Corporation

Uniserve (TSXV: USS) provides IT solutions, including Data Centre Solutions, Managed IT Services, and Business Internet, through its offices in Vancouver, Calgary, and Waterloo, serving approximately 3,000 SME customers. 

Follow us on social media

LinkedIn: https://www.linkedin.com/company/railtown-ai/ SUBSCRIBE FOR INVESTOR NEWS

Click here to receive our latest investor news alerts.

ON BEHALF OF THE BOARD

"Cory Brandolini"
Cory Brandolini, Chief Executive Officer

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will," "may", "should", "intends", "anticipates", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, the commencement of trading of the Company's common shares on the CSE, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269680

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trial 

Libtayo is the current standard of care in advanced CSCC; approval has the potential to change the treatment paradigm for patients in an earlier setting

TARRYTOWN, N.Y., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. The FDA evaluated Libtayo under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions. An additional regulatory application is also under review in the European Union, with a decision expected by the first half of 2026.

"Patients whose CSCC is at a high risk of recurrence following surgery and radiation often have the poorest outcomes. Until now, we lacked options to help prevent a devastating recurrence and immunotherapy was only available for patients with advanced CSCC who were no longer candidates for curative surgery or curative radiation,” said Vishal A. Patel, M.D., Associate Professor of Dermatology and of Medicine (Hematology/Oncology), George Washington University School of Medicine & Health Sciences and Director, Cutaneous Oncology Program, GW Cancer Center. “Many patients who undergo surgical resection of their CSCC are later found, on full pathological evaluation, to be at high risk of recurrence. As the first and only immunotherapy approved in the adjuvant setting, Libtayo represents a practice-changing opportunity for this patient population, backed by compelling data showcasing its ability to significantly improve disease-free survival.”

The FDA approval is based on data from the pivotal Phase 3 C-POST trial investigating adjuvant Libtayo versus placebo in patients with CSCC at high risk of recurrence after surgery and radiation. Results from the study, which were published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting earlier this year, showed that Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death compared to placebo in patients with CSCC at high risk of recurrence after surgery and radiation (hazard ratio [HR]: 0.32; 95% confidence interval [CI]: 0.20-0.51; p<0.0001).

The safety profile of Libtayo as adjuvant treatment of patients with CSCC at high risk of recurrence after surgery and radiation is consistent with the known safety profile for Libtayo monotherapy in advanced cancers. The most common adverse reactions as a single agent in adjuvant CSCC at high risk of recurrence (≥10%, with a difference between arms of ≥3% compared to placebo) were rash, pruritus, and hypothyroidism. Serious adverse reactions occurred in 18% of patients and those that occurred in ≥1% of patients in the Libtayo arm were pneumonia (1.5%), rash (1.5%), diarrhea (1.5%), adrenal insufficiency (1%), and arrhythmia (1%).

“This approval provides patients with CSCC at high risk of disease recurrence following surgery and radiation a much-needed option, as Libtayo is the only immunotherapy to demonstrate efficacy in this setting,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron. “Now with five FDA-approved indications, Libtayo is firmly established as a strong and versatile PD-1 inhibitor option for patients with a variety of cancers.”

“CSCC is one of the most common skin cancers in the world, with an estimated 1.8 million cases diagnosed each year in the U.S. alone. While it can often be treated successfully with surgery and radiation, many patients face serious risk of advanced disease recurrences,” said Samantha R. Guild, President, AIM at Skin Cancer Foundation. “This approval is wonderful news for people living with CSCC, and we commend Regeneron for its long-standing commitment to addressing needs in non-melanoma skin cancer through its pioneering research.”

Regeneron is committed to helping patients who have been prescribed Libtayo access their medication. The company has launched Libtayo Surround™, which offers financial and educational resources to help support patients throughout their treatment journey. For more information, patients can call 1-877-LIBTAYO (1-877-542-8296).

The approved supplemental Biologics License Application (sBLA) did not include Catalent Indiana, LLC as a filling site.

About Regeneron in Cancer
We aspire to turn revolutionary discoveries into medicines that can transform the lives of those impacted by cancer. Our team around the world is driven to solve the needs and challenges of those affected by one of the most serious diseases of our time.

Backed by our legacy of scientific innovation and a deep understanding of biology, genetics and the immune system, we’re pursuing potential therapies across more than 30 types of solid tumors and blood cancers. Our cancer strategy is powered by cutting-edge technologies and therapies that can be flexibly combined to investigate potentially transformative treatments for patients. Oncology assets in clinical development comprise nearly half of Regeneron’s pipeline, and include checkpoint inhibitors, bispecific antibodies and costimulatory bispecific antibodies. Our approved PD-1 inhibitor Libtayo serves as the backbone of many of our investigational combinations.

To complement our extensive in-house capabilities, we collaborate with patients, healthcare providers, governments, biopharma companies and each other to further our shared goals. Together, we are united in the mission to serve as a beacon of transformation in cancer care.

About Libtayo  
Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), CSCC that is advanced or at high risk of recurrence, advanced non-small cell lung cancer (NSCLC) and advanced cervical cancer.

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. FDA. Outside of the U.S., the generic name of Libtayo in its approved indications is cemiplimab.   

The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either conventional or novel therapeutic approaches for other solid tumors and blood cancers. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.

U.S. FDA-approved Indications   
Libtayo is a prescription medicine used to treat:  

Adults with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC): that has spread or cannot be cured by surgery or radiation, orto help prevent CSCC from coming back if your CSCC is at high risk of coming back after it has been removed by surgery and radiation. Adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI.  Adults with a type of lung cancer called non-small cell lung cancer (NSCLC). LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene.LIBTAYO may be used alone as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high “PD-L1,” and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene.
It is not known if Libtayo is safe and effective in children.   

IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS 

What is the most important information I should know about LIBTAYO?
LIBTAYO is a medicine that may treat certain cancers by working with your immune system. LIBTAYO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

Lung problems: cough, shortness of breath, or chest painIntestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or have blood or mucus, or severe stomach-area (abdomen) pain or tendernessLiver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach-area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than normalHormone gland problems: headache that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, or changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulnessKidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, or loss of appetiteSkin problems: rash, itching, skin blistering or peeling, painful sores or ulcers in mouth or nose, throat, or genital area, fever or flu-like symptoms, or swollen lymph nodesProblems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with LIBTAYO. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath or swelling of ankles, confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs, double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight, persistent or severe muscle pain or weakness, muscle cramps, low red blood cells, or bruisingInfusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: nausea, vomiting, chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain, or facial swellingRejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ or tissue transplant that you have hadComplications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with LIBTAYO. Your healthcare provider will monitor you for these complications Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with LIBTAYO. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects.

Before you receive LIBTAYO, tell your healthcare provider about all your medical conditions, including if you:

have immune system problems such as Crohn’s disease, ulcerative colitis, or lupushave received an organ or tissue transplant, including corneal transplanthave received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)have received radiation treatment to your chest areahave a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndromeare pregnant or plan to become pregnant. LIBTAYO can harm your unborn baby Females who are able to become pregnant:

Your healthcare provider will give you a pregnancy test before you start treatmentYou should use an effective method of birth control during your treatment and for at least 4 months after your last dose of LIBTAYO. Talk to your healthcare provider about birth control methods that you can use during this timeTell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LIBTAYO are breastfeeding or plan to breastfeed. It is not known if LIBTAYO passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of LIBTAYO Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of LIBTAYO when used alone to treat CSCC that has spread or cannot be cured by surgery or radiation, BCC or NSCLC include tiredness, muscle or bone pain, rash, diarrhea, and low levels of red blood cells (anemia).

The most common side effects of LIBTAYO when used alone to help prevent CSCC from coming back include rash and itching.

The most common side effects of LIBTAYO when used in combination with platinum-containing chemotherapy to treat NSCLC include hair loss, muscle or bone pain, nausea, tiredness, numbness, pain, tingling, or burning in your hands or feet, and decreased appetite.

These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals at 1-877-542-8296.

Please see full Prescribing Information, including Medication Guide.  

About Regeneron's VelocImmune Technology  
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved or authorized fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo, Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.  

About Regeneron 
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Libtayo® (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (“CSCC”) at high risk of recurrence after surgery and radiation; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products (such as Libtayo) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including Libtayo for the treatment of adjuvant CSCC in the European Union, Libtayo as a monotherapy or in combination with either conventional or novel therapeutic approaches for other solid tumors and blood cancers, and Regeneron’s other oncology assets in clinical development referenced in this press release; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Libtayo) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended June 30, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Key Takeaways Astera Labs is expanding its PCIe 6 portfolio to meet the growing demand for AI infrastructure.
Amphenol's liquid cooling connectors and interconnect products are fueling strong order growth.
APH's broad market reach and 79.3% YTD gain outpace ALAB amid tougher macro conditions.

Astera Labs (ALAB - Free Report) and Amphenol (APH - Free Report) are major players in the connectivity and data center infrastructure space. While Astera Labs develops semiconductor-based connectivity solutions tailored for cloud and AI infrastructure, Amphenol specializes in interconnect and sensor technologies across diverse industries.

Per a Grand View Research report, the data center infrastructure management market was valued at around $3.06 billion in 2024 and is expected to register a CAGR of 17.3% from 2025 to 2030. Both ALAB and APH are expected to benefit from the rapid growth pace.

So, ALAB or APH — Which of these Connectivity stocks has the greater upside potential? Let’s find out.

The Case for ALABAstera Labs is rapidly expanding its portfolio to address the growing demands of AI infrastructure and connectivity solutions. It benefits from strong demand for its PCIe solutions, which is noteworthy.

ALAB’s increasing demand for AI platforms, particularly those leveraging high-performance GPUs and AI accelerators, drove strong design wins and sales for products like Aries Retimers, Taurus Smart Cable Modules and Scorpio Fabric Switches.

Expanding portfolio has been noteworthy. In 2025, Astera Labs announced that its PCIe 6 connectivity portfolio is ramping production to fast-track the deployment of modern AI platforms at scale. The offerings include new Aries 6 PCIe Smart Gearbox, Scorpio P-Series Smart Fabric Switches, Aries 6 PCIe/CXL Smart DSP Retimers, Aries 6 PCIe/CXL Smart Cable Modules (Aries 6 SCMs) and PCIe 6 over Optics Technology.

ALAB expects accelerated shipments of Scorpio P-Series switches and Aries 6 retimers on a customized rack-scale AI platform based on market-leading GPUs to boost top-line growth. Scorpio revenues are expected to account for more than 10% of total revenues in 2025, while becoming the largest product line for Astera Labs over the next several years.

The Case for APHAmphenol benefits from a diversified business model. Its strong portfolio of solutions, including high-technology interconnect products, is a key catalyst. Strong demand for high-speed and power interconnect products, which are critical components in next-gen IT systems, creates a long-term growth opportunity.

The company’s expanding portfolio has been noteworthy. In June 2025, Amphenol launched its UQD and UQDB liquid cooling connector series, designed to enhance thermal management in high-reliability systems like AI data centers, EV charging infrastructure and energy storage. Both series meet Open Compute Project standards and feature corrosion-resistant materials, leak-free seals and tool-free integration for demanding liquid-cooled environments.

APH’s strong portfolio is helping drive order growth, which jumped 36% year over year and 4% sequentially to $5.523 billion, resulting in a book-to-bill ratio of 0.98:1 in the second quarter of 2025. Amphenol’s expanding portfolio of fiber optic, power, antenna and sensor technologies continues to gain traction across datacom, aerospace and defense markets.

Price Performance and Valuation of ALAB and APHIn the year-to-date period, ALAB and APH’s shares have gained 60.2% and 79.3%, respectively. The outperformance in Amphenol’s stock can be attributed to its robust and diversified portfolio.

Despite ALAB’s strong portfolio and expanding partner base, the company is suffering from challenging macroeconomic uncertainties and stiff competition.

ALAB and Amphenol Stock Performance
Image Source: Zacks Investment Research

Valuation-wise, ALAB and APH shares are currently overvalued as suggested by a Value Score of D and F, respectively.

In terms of forward 12-month Price/Sales, ALAB shares are trading at 37.34X, higher than Amphenol’s 6.56X.

ALAB and Amphenol Valuation
Image Source: Zacks Investment Research

How Do Earnings Estimates Compare for ALAB & APH?The Zacks Consensus Estimate for ALAB’s 2025 earnings is currently pegged at $1.58 per share, which has remained unchanged over the past 30 days, indicating an 88.10% year-over-year rise.

The Zacks Consensus Estimate for Amphenol’s 2025 earnings is currently pegged at $3.03 per share, which has increased by a penny over the past 30 days, indicating a 60.32% year-over-year rise.

ConclusionWhile both ALAB and Amphenol are well-positioned to capitalize on the booming connectivity and data center infrastructure space, APH appears to be the stronger bet given its diversified revenue streams, strong order growth and broader market exposure.

Macroeconomic challenges, including higher tariffs and uncertainty over trade policy, are a headwind for semiconductor companies, including Astera Labs. These, along with changing export restrictions, are expected to negatively impact demand across the AI and cloud infrastructure markets.

Currently, Amphenol has a Zacks Rank #2 (Buy), making the stock a stronger pick than Astera Labs, which has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways AEO drives growth through digital investments, store optimization and brand expansion efforts.Aerie sales rose 3.2% in Q2 2025, with comps up 3%, reinforcing its strength in activewear.AEO plans 30 new Aerie/offline stores, 40-50 remodels and 35-40 closures to streamline operations.
American Eagle Outfitters, Inc. (AEO - Free Report) is actively executing its strategic initiatives, aimed at driving long-term growth, enhancing operational efficiency and improving agility. The company has been investing in its digital platform to grow its e-commerce business and enrich customer experience. AEO has been witnessing a spectacular response to its Aerie brand for quite some time.

The company is focused on building brand awareness and expanding into new categories. The ongoing momentum and market share growth in OFFL/NE Activewear are Aerie’s most promising long-term growth drivers.  AEO is focused on reinvigorating the brand’s growth. During the second quarter of fiscal 2025, revenues at Aerie jumped 3.2% year over year while the brand’s comparable store sales (comps) rose 3%. We expect sales for Aerie to increase 4.1% for the third quarter and 1.3% year over year for fiscal 2025.

The company is prioritizing investments across its digital channel, with foundational improvements to the shopping experience. It focuses on optimizing its store fleet to ensure the best locations, offering a seamless customer experience and tapping into additional growth opportunities. This year, the company is on track to open approximately 30 Aerie and offline locations and remodel 40-50 AE stores to feature a modern design. It anticipates shutting down 35-40 American Eagle locations by the end of the year.

The company has also been making inventory-management efforts. AEO has been navigating tariffs and implementing several mitigation strategies, involving partnering with its sourcing vendors to cut costs. Additionally, the company is diversifying its supply chain and focusing on reducing its sourcing exposure to China. It is focused on building upon its sales momentum, managing costs and making continued improvements to deliver profitability. For the third and fourth quarters of fiscal 2025, the company expects comps to rise in the low single digits.

AEO’s Price Performance, Valuation and EstimatesAmerican Eagle’s shares have lost 6.8% year to date compared with the industry’s 11.6% decline.

Image Source: Zacks Investment Research

From a valuation standpoint, AEO trades at a forward price-to-earnings ratio of 12.22X compared with the industry’s average of 17.7X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for AEO’s fiscal 2025 earnings per share (EPS) indicates a year-over-year decline of 37.4% while that of fiscal 2026 shows growth of 25.1%. The company’s EPS estimate for fiscal 2025 and fiscal 2026 has moved north in the past 30 days.

Image Source: Zacks Investment Research

American Eagle currently carries a Zacks Rank #3 (Hold).

Eye These Solid Picks in RetailLevi Strauss & Co. (LEVI - Free Report) , designer and marketer of jeans, casual wear and related accessories, currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The consensus estimate for Levi Strauss’ current financial-year EPS indicates growth of 4% from the year-ago figure. LEVI delivered an average earnings surprise of 25.9% in the trailing four quarters.

Genesco Inc. (GCO - Free Report) operates as a retailer and wholesaler of footwear, apparel and accessories, carrying a Zacks Rank #2 (Buy) at present. GCO delivered a trailing four-quarter earnings surprise of 32.4%, on average.

The Zacks Consensus Estimate for Genesco’s current fiscal-year EPS and sales indicates growth of 71.3% and 3.7%, respectively, from the year-ago period’s reported figures.

Allbirds, Inc. (BIRD - Free Report) , a lifestyle brand, currently has a Zacks Rank of 2. The company delivered a trailing four-quarter earnings surprise of 20.7%, on average.

The Zacks Consensus Estimate for BIRD’s current financial-year EPS indicates growth of 18% from the year-ago figure.